Alkermes Bounces Back -- but Not Enough

Alkermes (NASDAQ: ALKS) turned in a solid-enough quarter, but a pullback in guidance for its growth-driver antipsychotic drug Aristada led investors to fret over the biotech's near-term future.

Metric

Q2 2019

Continue reading

Quelle Fool.com